Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

3.080 -0.150 (-4.64%)
Streaming Delayed Price Updated: 11:00 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 23Andme Holding Co.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
From 23andMe, Inc.
Via GlobeNewswire
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
23andMe restructures, cutting 40% of its workforce and ending its therapeutic programs to save $35 million annually while exploring strategic alternatives. 
Via Benzinga
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Outlook For 23andMe Holding
Via Benzinga
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
From 23andMe, Inc.
Via GlobeNewswire
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q2 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe Regains Compliance With Nasdaq Listing Requirements
From 23andMe, Inc.
Via GlobeNewswire
23andMe Appoints Three New Independent Directors to Board
From 23andMe, Inc.
Via GlobeNewswire
ASML's Latest Chapter in the Semiconductor Story
We've also got a look at genetic testing company 23andMe . 
Via The Motley Fool
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
The new African American Genetic Groups feature traces customers' ancestral connections from before the early-to-mid-20th century migrations to more than 200 communities in Southern states 
From 23andMe, Inc.
Via GlobeNewswire
Author Alok Sama on OpenAI, Bubbles, and When to Sell
We're talking tech. 
Via The Motley Fool
23andMe Announces Completion of 1-for-20 Reverse Stock Split
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces 1-for-20 Reverse Stock Split
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Mathew Knowles as New Brand Ambassador
Collaboration to help increase awareness of the power of genetic testing when it comes to learning about personal health risks 
From 23andMe, Inc.
Via GlobeNewswire
Legal Battle Brews Over 23andMe's Customer Data Breach Settlement And Arbitration Claimants
Lawyer raises objections to 23andMe's proposed $30 million settlement, arguing it undermines arbitration rights for 5,000 customers following a data breach. The court is set to review the case in late... 
Via Benzinga
Topics Data Breach
Exposures Information Security
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics 
From 23andMe, Inc.
Via GlobeNewswire
Independent Board Members Of Penny Stock 23andMe Resign, Call Out CEO Anne Wojcicki For Not 'Actionable Proposal' Despite Ample Time
23andMe's independent board members resigned after months of waiting for Anne Wojcicki's fully financed proposal to take the company private. 
Via Benzinga
General Mills, Steelcase And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Independent Directors of 23andMe Resign from Board
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
From 23andMe, Inc.
Via GlobeNewswire
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse population 
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
From 23andMe, Inc.
Via GlobeNewswire
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
In conjunction with this new offering, 23andMe, Lemonaid Health’s parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s 
From 23andMe, Inc.
Via GlobeNewswire
ME Stock Earnings: 23andMe Holding Beats EPS, Misses Revenue for Q1 2025
ME stock results show that 23andMe Holding beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025. 
Via InvestorPlace
23andMe Reports First Quarter Fiscal 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.